Controlled Human Infection Model
Faced with increasing pressures on timelines and budgets, clinical research practices aimed at developing prophylactic and curative treatments for infectious diseases need to continuously evolve in order to ensure effective and efficient pipeline development. Pathogenesis of infectious diseases in animal models is significantly different from pathogenesis occurring in humans, further complicating translation of treatment efficacy, correlates of protection and outcome measures from animal models to human field trials. To meet the demand for improved prognostic value, SGS has set up a unique, European-based, Controlled Human Infection Model (CHIM) with a benchmark containment facility within its Clinical Pharmacology Unit (CPU) on the grounds of the University Hospital Antwerp in Edegem, Belgium, thus enhancing its existing service offering for clients in the field of infectious diseases and vaccine development.
CHIM studies have been proven to • Reduce costs through accelerated development of pipelines • Provide early efficacy data, enabling rapid candidate selection • Prospectively translate animal performance data to human endpoints and healthy volunteer data to outcomes in the field
• Define correlates of protection and outcome measures related to vaccine efficacy to be carried through in the further development enhancing chance of success of field trials
Made with FlippingBook. PDF to flipbook with ease